Human Trials of Experimental Coronavirus Vaccine Begin in U.S.

WEDNESDAY, May 6, 2020 (HealthDay News) — An experimental coronavirus vaccine began human trials in the United States on Monday, Pfizer and the German pharmaceutical company BioNTech said.

If the trials show that the vaccine is effective, it could be available for emergency use in the United States as early as September, The New York Times reported.

The experimental vaccine, called BNT162, is being jointly developed by the two companies and the first human trials of the vaccine began in Germany last month.